Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | CCR8 | P51685 | 2/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24613098 | 0.85 | PDE3B (0.32) | NOS3NOS2 | |
| SCHEMBL12895997 | 0.81 | NOS2 (0.48) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL10105612 | 0.79 | NOS3 (0.32) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL21540038 | 0.78 | NUDT1 (0.45) | — | |
| SCHEMBL20285913 | 0.77 | TDO2 (0.33) | NOS3NOS2 | |
| SCHEMBL14803298 | 0.77 | TRPA1 (0.33) | NOS3NOS2 | |
| SCHEMBL25927976 | 0.77 | PRKCI (0.31) | NOS3NOS2 | |
| SCHEMBL24691977 | 0.74 | ROCK2 (0.33) | — | |
| SCHEMBL24691979 | 0.74 | NOS3 (0.33) | NOS3NOS2 | |
| SCHEMBL19203777 | 0.74 | ACHE (0.36) | CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | NOS3 2901/4885NOS2 2386/4885CCR1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.